Drug intelligence / Profile preview

gilvetmab

Development stage: Unknown
Lead developer: Merck Animal Health
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**Gilvetmab** is a caninized monoclonal antibody developed by Merck Animal Health as the first immune checkpoint inhibitor for veterinary use in dogs. It binds to canine programmed cell death receptor-1 (PD-1) on CD4+ and CD8+ T lymphocytes, blocking the interaction with PD-L1/L2 to prevent immune suppression by cancer cells, thereby reactivating the dog's immune system to attack tumors. It is conditionally approved by the USDA for treating stage I-III mast cell tumors (MCTs) and stage II-III melanomas, with clinical trials showing 73% tumor shrinkage or stabilization in MCTs and 60% in melanomas over 20 weeks, and it is administered intravenously every 2 weeks.[1][2][4][7][10]

Brand names: Gilvetmab

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on gilvetmab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gilvetmab.

Explore the full profile